Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.53 |
| ▸ | HTR1A | P08908 | 4/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.53 |
| ▸ | HTR2A | P28223 | 3/20 | 0.53 |
| ▸ | HTR7 | P34969 | 3/20 | 0.53 |
| ▸ | HTR6 | P50406 | 3/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 7/20 | 0.52 |
| ▸ | HTR1B | P28222 | 5/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5388166 | 0.99 | HTR1D (0.53) | DRD2HTR1ASLC6A4HTR2AHTR7 | |
| SCHEMBL5404487 | 0.97 | ADRA1D (0.53) | DRD2HTR1ASLC6A4HTR2AHTR7 | |
| SCHEMBL5380932 | 0.94 | OPRM1 (0.52) | DRD2HTR1ASLC6A4HTR2AHTR7 | |
| SCHEMBL5394671 | 0.88 | OPRM1 (0.53) | HTR2AHTR7ADRA1D | |
| SCHEMBL5389484 | 0.85 | ADRA1D (0.58) | DRD2HTR1ASLC6A4HTR2AHTR7 | |
| SCHEMBL5393529 | 0.85 | ADRA1D (0.57) | DRD2HTR1ASLC6A4HTR2AHTR7 | |
| SCHEMBL5380731 | 0.85 | MAPT (0.49) | SLC6A4HTR2AHTR7ADRA1DADRA1B | |
| SCHEMBL5394770 | 0.84 | ADRA1D (0.64) | DRD2HTR1ASLC6A4HTR2AHTR7 | |
| SCHEMBL5388989 | 0.84 | ADRA1D (0.60) | DRD2HTR1ASLC6A4HTR2AHTR7 | |
| SCHEMBL5401439 | 0.83 | ADRA1D (0.63) | DRD2HTR1ASLC6A4HTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1468996-B1 | Indole derivatives for the treatment of CNS disorders | LUNDBECK & CO AS H (DK) | 2007-09-26 | — | — | EP | claimed |
| US-6890916-B2 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2005-05-10 | — | — | US | claimed |
| EP-1468996-A1 | Indole derivatives for the treatment of CNS disorders | H. Lundbeck A/S (DK) | 2004-10-20 | — | — | EP | claimed |
| US-20030191133-A1 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2003-10-09 | — | — | US | claimed |
| EP-1294710-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2003-03-26 | — | — | EP | claimed |
| WO-2001096328-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2001-12-20 | — | — | WO | claimed |
| US-7276508-B2 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2007-10-02 | — | — | US | disclosed |
| EP-1468996-B1 | Indole derivatives for the treatment of CNS disorders | LUNDBECK & CO AS H (DK) | 2007-09-26 | — | — | EP | disclosed |
| US-20050176729-A1 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2005-08-11 | — | — | US | disclosed |
| EP-1294710-B1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | LUNDBECK & CO AS H (DK) | 2005-06-08 | — | — | EP | disclosed |
| US-6890916-B2 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2005-05-10 | — | — | US | disclosed |
| EP-1468996-A1 | Indole derivatives for the treatment of CNS disorders | H. Lundbeck A/S (DK) | 2004-10-20 | — | — | EP | disclosed |
| US-20030191133-A1 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2003-10-09 | — | — | US | disclosed |
| CN-1446211-A | Indole derivatives for the treatment of CNS disorders | LUNDBECK & CO AS H (DK) | 2003-10-01 | — | — | CN | disclosed |
| EP-1294710-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001096328-A1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | H. LUNDBECK A/S (DK) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176729-A1 | Indole derivatives useful for the treatment of CNS disorders | HTR4, TPH1, SLC6A3 | DRD2 14/4885HTR1A 7/4885SLC6A4 4/4885 |
| US-20030191133-A1 | Indole derivatives useful for the treatment of CNS disorders | TPH1, CHRM1, TPH2 | DRD2 47/4885HTR1A 11/4885SLC6A4 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.